News | December 23, 2008

Amgen Asks FDA to Approve Inhibitor Used in Breast, Prostate Cancer Patients

December 23, 2008 - Amgen has submitted a Biologics License Application (BLA) with the FDA for denosumab, an investigational RANK Ligand inhibitor, as Amgen seeks FDA approval for treatment and prevention of postmenopausal osteoporosis (PMO) in women, and treatment and prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer.

The BLA submission contains data from six Phase 3 trials involving more than 11,000 patients.

"Two Phase 3 pivotal studies with fracture endpoints, in the PMO and prostate cancer settings, demonstrated denosumab’s ability to reduce fracture, and all six studies showed denosumab’s ability to increase bone mineral density at all skeletal sites measured," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen.

Amgen also intends to submit a marketing application shortly in the European Union, Switzerland, Canada and Australia for use of denosumab in these indications.

According to the American Cancer Society, in the U.S., prostate cancer is the most common cancer in men and breast cancer is the most common cancer in women. It is common for prostate cancer and breast cancer patients to receive hormone ablation therapies that can lead to a decrease in bone mass and increased risk of fractures. Currently there are no approved therapies for bone loss in patients undergoing hormone ablation for either prostate or breast cancer.

For more information: www.amgen.com

Related Content

Comparison of Screening Recommendations Supports Annual Mammography
News | Mammography | August 22, 2017
When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
The ASPIRE Cristalle FFDM system with DBT combines Fujifilm’s state-of-the-art hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow
News | Women's Health | August 01, 2017
Fujifilm Medical Systems U.S.A., Inc. announced that The Mammography Center of Monterey, an ACR-accredited breast...
Sponsored Content | Videos | Breast Imaging | July 28, 2017
Nancy Cappello, Ph.D., executive director and founder of Are You Dense Inc. and Are You Dense Advocacy, explains how
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Kubtec Launches New Website For Digital Imaging and Irradiation Products
News | Digital Radiography (DR) | July 20, 2017
Kubtec announced the launch a new website focused on the applications of digital X-ray imaging and irradiation for...
Volpara Solutions to Showcase Volpara Enterprise DDP Software at AHRA 2017
News | Mammography | July 11, 2017
Volpara Solutions Inc. will showcase its new Volpara Enterprise DDP software at the Association for Medical Imaging...
Fujifilm Showcases Digital Radiography, Mammography Innovations at AHRA 2017
News | Digital Radiography (DR) | July 06, 2017
Fujifilm Medical Systems U.S.A. Inc. will present its comprehensive portfolio of digital radiography (DR) and...
Feature | Breast Density | July 05, 2017 | By Nancy M. Cappello, Ph.D.
Two decades of research on the masking risk of dense breast tissue by mammography screening is indisputable. As the...
Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50
News | Mammography | June 30, 2017
June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the
Overlay Init